Skip to main content

Table 1 Clinical characteristics of all samples used in the study

From: circRNA circAF4 functions as an oncogene to regulate MLL-AF4 fusion protein expression and inhibit MLL leukemia progression

Type of sample

Characteristics

Median (range)

No. (%)

MLL-AF4

(N = 7)

Age at diagnosis, years

1 (0.25–7)

 

Sex

  

 Male

 

4 (57.1)

 Female

 

3 (42.9)

Immunophenotype

  

 B

 

7 (100)

 T

 

0 (0)

WBC count, × 109/L

89 (18.29–173)

 

Risk group

  

 H

 

4 (57.1)

 M

 

0 (0)

 S

 

0 (0)

 N/A

 

3 (42.9)

MLL-other fusion type

(N = 15)

Age at diagnosis, years

4 (0.33–13)

 

Sex

  

 Male

 

11 (73.4)

 Female

 

4 (26.6)

Immunophenotype

  

 B

 

10 (66.7)

 T

 

5 (33.3)

Fusion gene

  

 MLL-AF9

 

1 (6.7)

 MLL-ENL

 

2 (13.3)

 MLL-AF10

 

1 (6.7)

 N/A

 

11 (73.3)

WBC count, × 109/L

72 (4.63–370)

 

Risk group

  

 H

 

9 (60)

 M

 

3 (20)

 S

 

1 (6.7)

 N/A

 

2 (13.3)

MLL-wt

(N = 30)

Age at diagnosis, years

8 (1–13)

 

Sex

  

 Male

 

19 (63.3)

 Female

 

11 (36.7)

Immunophenotype

  

 B

 

12 (40.0)

 T

 

12 (40.0)

 N/A

 

6 (20.0)

WBC count, × 109/L

31 (2–632.47)

 

Risk group

  

 H

 

7 (23.3)

 M

 

12 (40)

 S

 

5 (16.7)

 N/A

 

6 (20)

Normal (N = 16)

  

16 (100)